Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.

Detalhes bibliográficos

Principais autores:	Mencinger Marina, Mangaroski Dusan, Bokal Urska
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Sciendo 2021-05-01
coleção:	Radiology and Oncology
Assuntos:	pd-l1 inhibitor urothelial cancer bladder atezolizumab overall survival immune checkpoint inhibitor prognostic factors
Acesso em linha:	https://doi.org/10.2478/raon-2021-0021
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!